[1] |
Moser AB, Fatemi A. Newborn screening and emerging therapies for X-linked adrenoleukodystrophy. JAMA Neurol, 2018, 75(10): 1175-1176.
doi: 10.1001/jamaneurol.2018.1585
pmid: 29946687
|
[2] |
Kemp S, Huffnagel IC, Linthorst GE, Wanders RJ, Engelen M. Adrenoleukodystrophy-neuroendocrine pathogenesis and redefinition of natural history. Nat Rev Endocrinol, 2016, 12(10): 606-615.
doi: 10.1038/nrendo.2016.90
|
[3] |
Ashrafi MR, Amanat M, Garshasbi M, Kameli R, Nilipour Y, Heidari M, Rezaei Z, Tavasoli AR. An update on clinical, pathological, diagnostic, and therapeutic perspectives of childhood leukodystrophies. Expert Rev Neurother, 2020, 20(1): 65-84.
doi: 10.1080/14737175.2020.1699060
pmid: 31829048
|
[4] |
Engelen M, Kemp S, de Visser M, van Geel BM, Wanders RJA, Aubourg P, Poll-The BT. X-linked adrenoleukodystrophy (X-Ald): clinical presentation and guidelines for diagnosis, follow-up and management. Orphanet J Rare Dis, 2012, 7: 51.
doi: 10.1186/1750-1172-7-51
pmid: 22889154
|
[5] |
Dubey P, Raymond GV, Moser AB, Kharkar S, Bezman L, Moser HW. Adrenal insufficiency in asymptomatic adrenoleukodystrophy patients identified by very long-chain fatty acid screening. J Pediatr, 2005, 146(4): 528-532.
doi: 10.1016/j.jpeds.2004.10.067
|
[6] |
Lee H, Ko JM, Lee SH. Generalized skin hyperpigmentation as the only manifestation of X-linked adrenoleucodystrophy. Br J Dermatol, 2020, 182(1): 239-240.
doi: 10.1111/bjd.18310
pmid: 31269232
|
[7] |
Nan M, Liu YF, Zhao X, Yuan N, Chai SB, Zhang XM. A pedigree of X-linked adrenoleukodystrophy with hypocorticism. Chin J Intern Med, 2021, 60(2): 152-155.
doi: 10.3760/cma.j.cn112138-20200417-00384
pmid: 33503729
|
|
南敏, 刘玉芳, 赵心, 袁宁, 柴三葆, 张晓梅. 一个以肾上腺皮质功能减退起病的X连锁肾上腺脑白质营养不良家系报道. 中华内科杂志, 2021, 60(2): 152-155.
doi: 10.3760/cma.j.cn112138-20200417-00384
pmid: 33503729
|
[8] |
Barceló A, Girós M, Sarde CO, Pintos G, Mandel JL, Pàmpols T, Estivill X. De novo missense mutation Y174s in exon 1 of the adrenoleukodystrophy (Ald) gene. Hum Genet, 1995, 95(2): 235-237.
pmid: 7860075
|
[9] |
Horikawa Y, Enya M, Yoshikura N, Kitagawa J, Takashima S, Shimozawa N, Takeda J. A first case of adrenomyeloneuropathy with mutation Y174S of the adrenoleukodystrophy gene. Neuro Endocrinol Lett, 2017, 38(1): 13-18.
|
[10] |
Ping LL, Bao XH, Wang AH, Pan H, Wu Y, Xiong H, Jiang YW, Qin J, Wu XR. Clinical features and genotype-phenotype studies of 89 Chinese patients with X-linked adrenoleukodystrophy. Chin J Intern Med, 2007, 45(3): 203-207.
|
|
平莉莉, 包新华, 王爱花, 潘虹, 吴晔, 熊晖, 姜玉武, 秦炯, 吴希如. X连锁肾上腺脑白质营养不良89例临床特征及基因型/表型关系. 中华儿科杂志, 2007, 45(3): 203-207.
|
[11] |
Rattay TW, Rautenberg M, Söhn AS, Hengel H, Traschütz A, Röben B, Hayer SN, Schüle R, Wiethoff S, Zeltner L, Haack TB, Cegan A, Schöls L, Schleicher E, Peter A. Defining diagnostic cutoffs in neurological patients for serum very long chain fatty acids (Vlcfa) in genetically confirmed X-adrenoleukodystrophy. Sci Rep, 2020, 10(1): 15093.
doi: 10.1038/s41598-020-71248-8
pmid: 32934269
|
[12] |
Liberato AP, Mallack EJ, Aziz-Bose R, Hayden D, Lauer A, Caruso PA, Musolino PL, Eichler FS. MRI brain lesions in asymptomatic boys with X-linked adrenoleukodystrophy. Neurology, 2019, 92(15): e1698-e1708.
doi: 10.1212/WNL.0000000000007294
|
[13] |
Mallack EJ, Turk BR, Yan H, Price C, Demetres M, Moser AB, Becker C, Hollandsworth K, Adang L, Vanderver A, Van Haren K, Ruzhnikov M, Kurtzberg J, Maegawa G, Orchard PJ, Lund TC, Raymond GV, Regelmann M, Orsini JJ, Seeger E, Kemp S, Eichler F, Fatemi A. Mri Surveillance of boys with X-linked adrenoleukodystrophy identified by newborn screening: meta-analysis and consensus guidelines. J Inherit Metab Dis, 2021, 44(3): 728-739.
doi: 10.1002/jimd.12356
|
[14] |
Mahmood A, Raymond GV, Dubey P, Peters C, Moser HW. Survival analysis of haematopoietic cell transplantation for childhood cerebral X-linked adrenoleukodystrophy: a comparison study. Lancet Neurol, 2007, 6(8): 687-692.
pmid: 17618834
|
[15] |
Yu JY, Chen T, Guo X, Zafar MI, Li HQ, Wang ZH, Zheng J. The role of oxidative stress and inflammation in X-link adrenoleukodystrophy. Front Nutr, 2022, 9: 864358.
doi: 10.3389/fnut.2022.864358
|
[16] |
Zhu J, Eichler F, Biffi A, Duncan CN, Williams DA, Majzoub JA. The changing face of adrenoleukodystrophy. Endocr Rev, 2020, 41(4): 577-593.
|
[17] |
Van Geel BM, Assies J, Haverkort EB, Koelman JH, Verbeeten B, Wanders RJ, Barth PG. Progression of abnormalities in adrenomyeloneuropathy and neurologically asymptomatic X-linked adrenoleukodystrophy despite treatment with "Lorenzo's Oil". J Neurol Neurosurg Psychiatry, 1999, 67(3): 290-299.
|
[18] |
Rasmussen M, Moser AB, Borel J, Khangoora S, Moser HW. Brain, liver, and adipose tissue erucic and very long chain fatty acid levels in adrenoleukodystrophy patients treated with glyceryl trierucate and trioleate oils (Lorenzo's Oil). Neurochem Res, 1994, 19(8): 1073-1082.
pmid: 7800117
|
[19] |
Eichler F, Duncan C, Musolino PL, Orchard PJ, De Oliveira S, Thrasher AJ, Armant M, Dansereau C, Lund TC, Miller WP, Raymond GV, Sankar R, Shah AJ, Sevin C, Gaspar HB, Gissen P, Amartino H, Bratkovic D, Smith NJC, Paker AM, Shamir E, O'Meara T, Davidson D, Aubourg P, Williams DA. Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy. N Engl J Med, 2017, 377(17): 1630-1638.
doi: 10.1056/NEJMoa1700554
|